Edgar Tracker

ALNY ALNYLAM PHARMACEUTICALS, INC.

Nasdaq · CIK 1178670 · Pharmaceutical Preparations

SEC company page

Public articles

ALNY · 10-Q

Filing note · 10-Q · filed 2026-07-30

Alnylam Pharmaceuticals: AMVUTTRA Drives Q2 Profitability Amid Rising Liabilities Alnylam Pharmaceuticals filed its 10 Q on July 30, 2026, detailing financial results for the quar…

Recent filings

–

Form Filed Title Accession
10-Q2026-07-3010-Q Article0001178670-26-000062
8-K2026-07-302.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits0001178670-26-000060
32026-06-03PRIMARY DOCUMENT0001178670-26-000046
8-K2026-05-275.02 Departure/Election of Directors or Principal Officers · 5.07 Submission of Matters to a Vote of Security Holders0001628280-26-038499
SCHEDULE 13G/A2026-05-14—0001422849-26-000061
SCHEDULE 13G/A2026-05-14—0001422848-26-000050
SCHEDULE 13G/A2026-05-06—0000315066-26-001107
10-Q2026-04-3010-Q0001628280-26-028605
8-K2026-04-302.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits0001628280-26-028601
SCHEDULE 13G2026-04-29—0002100119-26-000160
32026-04-07PRIMARY DOCUMENT0001178670-26-000012
ARS2026-04-06ARS0001140361-26-013365
DEFA14A2026-04-06DEFA14A0001628280-26-023924
DEF 14A2026-04-06DEF 14A0001628280-26-023923
SCHEDULE 13G/A2026-03-26—0000102909-26-000562
8-K2026-03-045.02 Departure/Election of Directors or Principal Officers0001628280-26-014728
S-82026-02-12S-80001628280-26-007687
10-K2026-02-1210-K0001628280-26-007497
8-K2026-02-122.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits0001628280-26-007491
8-K2026-01-122.02 Results of Operations and Financial Condition0001628280-26-001755